Both about US-listed Chinese stocks. So I give Tibet Pharmaceuticals a 85% chance of succeeding. Most management teams or Chinese entrepreneurs are fed up with the negative sentiment that pushed their shares to the brink. Going private relieves the company from Western obligations.
I think at the end those companies which go private will relist if good corporate governance is established. A lack of transparency will force many US-listed China Reverse Take Overs and other small Chinese stocks to reconsider a listing in the U.S.